other material
confidence high
sentiment neutral
materiality 0.60
Lixte Biotechnology cancels 500,000 options, awards equal RSUs vesting immediately to CEO, CFO, and directors
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- CEO Geordan Pursglove: 350,000 options cancelled, 350,000 RSUs awarded; CFO Peter Stazzone: 50,000 each.
- Directors Holloway, Primus, Felix, Sawyer: each 25,000 options cancelled and RSUs awarded.
- RSUs granted under 2020 Stock Incentive Plan and vested immediately on April 15, 2026.
- Committee states swap provides better retention/incentive for officers and directors.